
‘Keep Your Eyes on the Prize,' Says Top Investor About Nvidia Stock
Well, today is the day! The excitement is palpable as Nvidia Corporation (NASDAQ:NVDA) prepares to release its quarterly report after the market closes, with both seasoned investors and newcomers eagerly awaiting the Q1 FY 2026 results.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
While the company regularly outshoots both its guidance and the market expectations, the stars might not be aligned this time around due to larger macro concerns and issues specific to Nvidia and its semiconductor peers.
For instance, last month, the Trump administration informed Nvidia that it would need export licenses to sell its H20 GPUs to Chinese customers. As a result, Nvidia has announced that it will absorb approximately $5.5 billion in charges this quarter due to expenses associated with these H20 products.
However, Nvidia is still expected to deliver quarterly revenues around $43 billion – which would represent 66% year-over-year growth. While margins are slated to drop a few percentage points due to costs related to the Blackwell ramp, they are likely to remain north of 70%.
And yet, such are the weight of expectations on the undisputed data center leader that Nvidia's share price has dropped in the past following earnings releases, even after beating both top- and bottom-line projections.
So, what's on tap this time?
While top investor Rick Orford foresees some short-term volatility, he firmly believes that Nvidia is one to buy and hold for the long haul.
'Given its prospects and the current market conditions, I think Nvidia will not only recover from the current economic and government setbacks but will catapult even higher,' asserts the 5-star investor, who is among the very top 1% of TipRanks' stock pros.
Orford explains that aside from its gaming segment, Nvidia's revenues have been growing across the board. Even here, however, the investor points out that its 11% year-over-year revenue decrease last quarter was due to supply constraints, meaning that there should be improved figures this time around.
Moreover, Orford does not see any threats to Nvidia's place at the top of the AI pecking order. In other words, this money-maker will keep on powering away.
'Nvidia's Data Center segment will most likely continue to rake in massive profits from the ongoing AI revolution – can you name a company that can overthrow Nvidia in the next 5 to 10 years?,' Orford asks, rhetorically.
In addition, Nvidia stands to further benefit from the expanding autonomous vehicle market – which offers 'massive upside potential.' The company has already inked a number of deals with auto companies, such as Toyota, Tesla, and Mercedes-Benz, among others.
In other words, don't be distracted by any short-term volatility, sums up the investor, and keep your eyes firmly focused on longer term horizons.
'As a long-term investor, my 'Strong Buy' rating for Nvidia is for its long-term prospects only. And yes, that 5+ years and more,' concludes Orford. (To watch Rick Orford's track record, click here)
You won't find much disagreement on Wall Street. With 32 Buys, 4 Holds, and 1 Sell, NVDA boasts a Strong Buy consensus rating. Its 12-month average price target of $164.21 has an upside north of 20%. (See NVDA stock forecast)
To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Disclaimer: The opinions expressed in this article are solely those of the featured investor. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

National Post
an hour ago
- National Post
Fujirebio Expands Its Neuro Testing Portfolio With the Launch of the Fully Automated Lumipulse® G sTREM2 Assay for Research Use Only
Article content GENT, Belgium & MALVERN, Pa. & TOKYO — H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLEIA (chemiluminescent enzyme immunoassay) assay is available for Research Use Only (RUO) and allows for the quantitative measurement of soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2) in human cerebrospinal fluid (CSF) and blood within just 35 minutes. Article content sTREM2 is a promising biomarker of microglial activation, offering researchers insights into neuroinflammation linked to Alzheimer's and other neurodegenerative diseases. sTREM2 can be valuable for capturing the dynamics of inflammatory responses or for monitoring inflammatory modulators. This test complements Fujirebio's growing portfolio of neuro biomarkers, including GFAP, NfL, and pTau, and reinforces the company's leading position in advancing neuro biomarker research tools and diagnostics. Article content Article content 'By adding sTREM2 to our neuro portfolio, we're enabling a more comprehensive view of neurological disease mechanisms,' Article content said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. 'sTREM2 complements established biomarkers like GFAP, NfL, and pTau by adding essential insight into neuroinflammation – offering a more complete picture of the disease on a single platform.' Article content The new test allows researchers and clinical research professionals to further study and understand the potential clinical utility of this promising microglial biomarker. The availability of the assay on the fully automated random access LUMIPULSE G analyzers gives researchers access to convenient, accurate, and robust measurement of sTREM2. Already widely available for routine use in neurological disease testing worldwide, these analyzers meet all necessary quality, throughput, and regulatory requirements. Article content About Fujirebio Article content Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products. Article content Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. Article content Article content Article content Email: Article content pr@ Article content For investors and analysts: Article content Article content IR/SR Dept. Article content Article content Article content

CTV News
2 hours ago
- CTV News
CTV National News: Steel and aluminum tariffs doubled as Trump's trade war escalates
CTV National News: Steel and aluminum tariffs doubled as Trump's trade war escalates Prime Minister Carney is calling U.S. President Trump's doubling of steel and aluminum tariffs 'unlawful and unjustified'. Rachel Aiello has the latest.


CBC
2 hours ago
- CBC
Bank of Canada officials speak after interest rate announcement
Bank of Canada governor Tiff Macklem and senior deputy governor Carolyn Rogers give a statement and answer questions about the central bank's interest rate announcement.